The survival analysis of our MM screening cohort (n = 141) demonstrated the unfavorable prognostic value of miR-221/222 loss for disease outcome, as MM patients underexpressing miR-221/222 cluster in CD138+ plasma cells were at significantly higher risk for short-term relapse and worse survival following 1st-line chemotherapy. Here, SDC1 is linked to Miyoshi myopathy.